Melatonin Does Bind to Iron and Lead, But Is NOT a Clinically Recommended Chelating Agent
Melatonin has demonstrated metal-binding properties with both iron and lead in laboratory studies, but it is not approved or recommended as a chelating agent for iron overload or lead poisoning in clinical practice. The established medical chelators—deferoxamine, deferiprone, and deferasirox for iron overload 1, 2, and standard chelation protocols for lead poisoning 3—remain the evidence-based treatments.
Metal-Binding Properties: Laboratory Evidence
Melatonin does exhibit metal chelating capabilities in experimental settings:
- Iron binding: Electrochemical studies show melatonin forms complexes with both ferrous (Fe²⁺) and ferric (Fe³⁺) iron, with 95% chelating effect on ferrous ions at 60 µg/mL concentration—superior to α-tocopherol, BHA, and BHT 4
- Lead binding: Adsorptive voltammetry demonstrates melatonin binds lead, aluminum, cadmium, copper, and zinc in vitro 5
- Mechanism: The chelating property likely involves melatonin's indole structure, though electronic density functional calculations suggest lead/melatonin complexes are energetically feasible but not directly detectable by UV spectroscopy or NMR 6
Effects on Lead Toxicity: Animal Data Only
In rat models of subacute lead exposure, melatonin (10 mg/kg/day) showed:
- Lower blood lead levels and higher urinary/fecal lead excretion compared to lead-only treatment 6
- Increased hepatic metallothionein-2 (MT2) mRNA expression, potentially mediating lead redistribution 6
- Reduced oxidative damage from lead exposure 7
Critical limitation: These are animal studies with no human clinical trial data demonstrating efficacy or safety for lead poisoning treatment.
Clinical Reality: Not an Approved Chelator
For Iron Overload
The established iron chelators are 1, 2, 8:
- Deferoxamine (parenteral, hexadentate): 20-50 mg/kg/day subcutaneously for 8-12 hours, 5-7 nights weekly
- Deferiprone (oral, bidentate): 75-100 mg/kg/day divided three times daily
- Deferasirox (oral, tridentate): 20-40 mg/kg/day once daily
Target: Ferritin 50-100 µg/L for hemochromatosis 1; <1,000 ng/mL for transfusion-dependent patients 2
Melatonin is mentioned only once in iron overload guidelines—as a dietary supplement with no established role 1. Despite theoretical iron-chelating properties 9, 10, no clinical trials support its use for iron overload management.
For Lead Poisoning
Standard chelation for lead toxicity 3:
- Blood lead ≥100 µg/dL: Almost always warrants chelation
- Blood lead 80-99 µg/dL: Consider chelation with or without symptoms
- Blood lead 50-79 µg/dL: Case-by-case basis for symptomatic patients
Approved chelators include succimer, EDTA, dimercaprol, and penicillamine—not melatonin.
Why Melatonin Is Not Used Clinically
- No human efficacy data: All evidence is from in vitro studies or animal models 6, 4, 5
- Unproven clinical benefit: A randomized trial of succimer in children with blood lead 22-44 µg/dL showed no cognitive improvement despite lowering blood lead 3—melatonin has no comparable human data
- Regulatory status: Melatonin is marketed as a dietary supplement for sleep 11, not as a chelating agent
- Established alternatives exist: FDA-approved chelators have decades of clinical use with known safety profiles
Theoretical Mechanisms Beyond Chelation
Melatonin may reduce metal toxicity through 9, 7, 10:
- Direct free radical scavenging (83% H₂O₂ scavenging at 60 µg/mL 4)
- Inhibition of iron-dependent lipid peroxidation
- Modulation of ferroptosis pathways
- Antioxidant enzyme stimulation
These mechanisms suggest potential as adjunctive therapy for oxidative damage, not primary chelation.
Clinical Bottom Line
Do not use melatonin as a chelating agent for iron overload or lead poisoning. While laboratory studies confirm metal-binding properties 4, 5, the absence of human clinical trials, lack of regulatory approval, and availability of proven chelators make melatonin inappropriate for these indications. For iron overload, use deferoxamine, deferiprone, or deferasirox per established guidelines 1, 2, 8. For lead poisoning requiring chelation, consult toxicology and use approved agents 3.
Melatonin's role remains limited to its approved indication as a sleep aid 11, with potential future research into oxidative stress mitigation in metal toxicity—but not as primary chelation therapy.